Brief: Onxeo Confirms Preclinical Profile Of OX401

Valerio Therapeutics SA

25/06/2020 06:16

June 25 (Reuters) - ONXEO SA  C4X.PA :
    * ONXEO CONFIRMS IN PRECLINICAL STUDIES THE PROFILE OF
OX401, A
POTENT PARP AGONIST WITH STRONG ANTI-TUMOR ACTIVITY AND
IMMUNOLOGICAL PROPERTIES
    * PRECLINICAL PROGRAM ALREADY COMPLETED HAS CONFIRMED KEY
PROPERTIES OF THIS NEW COMPOUND
    * TRANSLATIONAL STUDIES WILL ALLOW TO BEST PREPARE FOR ENTRY
INTO
CLINIC, WHICH COULD TAKE PLACE WITHIN 18 TO 24 MONTHS

Source text for Eikon:  ID:nBw5424RVa 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))